The state of Maryland currently has 4 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA). The primary objective is to evaluate the effect of seladelpar treatment at Week 52 compared to placebo based on normalization of alkaline phosphatase (ALP) defined by a composite endpoint of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2025
Locations: Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Recruiting
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Mercy Medical Center - Mcauley Plaza, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis
A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.
Recruiting
A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis